CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization
- PMID: 309306
- PMCID: PMC352474
- DOI: 10.1128/AAC.14.3.414
CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization
Abstract
CP-45,899 {3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 4,4-dioxide, [2S-(2alpha,5alpha)]} is an irreversible inhibitor of several bacterial penicillinases and cephalosporinases. In the presence of low concentrations of CP-45,899, ampicillin and other beta-lactams readily inhibit the growth of a variety of resistant bacteria that contain beta-lactamases. CP-45,899 used alone displays only weak antibacterial activity, with the notable exception of its potent effects on susceptible and resistant strains of Neisseria gonorrhoeae. CP-45,899 appears to be somewhat less potent but markedly more stable (in aqueous solution) than the recently described beta-lactamase inhibitor clavulanic acid. The spectrum extensions provided by the two compounds are similar. A 1:1 mixture of CP-45,899 and ampicillin displays marked antimicrobial activity in mice experimentally infected with ampicillin-resistant Staphylococcus aureus, Haemophilus influenzae, Klebsiella pneumoniae, and Proteus vulgaris.
Similar articles
-
Comparative inhibition beta-lactamases by novel beta-lactam compounds.Antimicrob Agents Chemother. 1979 Feb;15(2):171-6. doi: 10.1128/AAC.15.2.171. Antimicrob Agents Chemother. 1979. PMID: 311616 Free PMC article.
-
A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor.J Antibiot (Tokyo). 1978 Dec;31(12):1238-44. doi: 10.7164/antibiotics.31.1238. J Antibiot (Tokyo). 1978. PMID: 310815
-
Clavulanic acid, a novel inhibitor of beta-lactamases.Antimicrob Agents Chemother. 1978 Nov;14(5):650-5. doi: 10.1128/AAC.14.5.650. Antimicrob Agents Chemother. 1978. PMID: 310279 Free PMC article.
-
Beta-lactamase inhibitors from laboratory to clinic.Clin Microbiol Rev. 1988 Jan;1(1):109-23. doi: 10.1128/CMR.1.1.109. Clin Microbiol Rev. 1988. PMID: 3060240 Free PMC article. Review.
-
Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition.Am J Health Syst Pharm. 1995 Mar 15;52(6 Suppl 2):S15-22. doi: 10.1093/ajhp/52.6_Suppl_2.S15. Am J Health Syst Pharm. 1995. PMID: 7606585 Review.
Cited by
-
Single dose intramuscular sulbactam and ampicillin in treating acute uncomplicated gonorrhoea.Genitourin Med. 1985 Jun;61(3):209. doi: 10.1136/sti.61.3.209. Genitourin Med. 1985. PMID: 2989156 Free PMC article. No abstract available.
-
Kinetic and physical studies of beta-lactamase inhibition by a novel penem, BRL 42715.Biochem J. 1994 Nov 1;303 ( Pt 3)(Pt 3):825-30. doi: 10.1042/bj3030825. Biochem J. 1994. PMID: 7980451 Free PMC article.
-
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration.Antimicrob Agents Chemother. 1982 Apr;21(4):565-7. doi: 10.1128/AAC.21.4.565. Antimicrob Agents Chemother. 1982. PMID: 6282211 Free PMC article.
-
Pharmacokinetics of an ampicillin-sulbactam combination after intravenous and intramuscular administration to sheep.Can J Vet Res. 1999 Jan;63(1):25-30. Can J Vet Res. 1999. PMID: 9918330 Free PMC article.
-
Sulbactam/ampicillin versus cefotaxime as initial therapy in serious soft tissue, joint and bone infections.Drugs. 1988;35 Suppl 7:46-52. doi: 10.2165/00003495-198800357-00012. Drugs. 1988. PMID: 3265378 Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous